100 related articles for article (PubMed ID: 29670383)
21. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis.
Bangalore S; Shah R; Gao X; Pappadopulos E; Deshpande CG; Shelbaya A; Prieto R; Stephens J; Chambers R; Schepman P; McIntyre RS
J Med Econ; 2020 Mar; 23(3):262-270. PubMed ID: 31665949
[No Abstract] [Full Text] [Related]
22. Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event.
Butler J; Djatche LM; Sawhney B; Chakladar S; Yang L; Brady JE; Yang M
Adv Ther; 2020 Sep; 37(9):4015-4032. PubMed ID: 32761552
[TBL] [Abstract][Full Text] [Related]
23. An economic model of long-term use of celecoxib in patients with osteoarthritis.
Loyd M; Rublee D; Jacobs P
BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
[TBL] [Abstract][Full Text] [Related]
24. Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls.
Bedenbaugh AV; Bonafede M; Marchlewicz EH; Lee V; Tambiah J
Clinicoecon Outcomes Res; 2021; 13():421-435. PubMed ID: 34054301
[TBL] [Abstract][Full Text] [Related]
25. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
[TBL] [Abstract][Full Text] [Related]
26. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Brereton N; Pennington B; Ekelund M; Akehurst R
J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
[TBL] [Abstract][Full Text] [Related]
27. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
28. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Bonafede M; Jing Y; Gdovin Bergeson J; Liffmann D; Makenbaeva D; Graham J; Deitelzweig SB
Hosp Pract (1995); 2011 Aug; 39(3):16-22. PubMed ID: 21881388
[TBL] [Abstract][Full Text] [Related]
29. Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients.
Boytsov N; Harrold LR; Mason MA; Gaich CL; Zhang X; Larmore CJ; Rebello S; Araujo AB
Curr Med Res Opin; 2016 Dec; 32(12):1959-1967. PubMed ID: 27558077
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
32. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.
Zhou Z; Fan Y; Tang W; Liu X; Thomason D; Zhou ZY; Macaulay D; Fischer A
J Rheumatol; 2019 Aug; 46(8):920-927. PubMed ID: 30770505
[TBL] [Abstract][Full Text] [Related]
33. A Retrospective Claims-Based Study Evaluating Clinical and Economic Burden Among Patients With Moderate to Severe Osteoarthritis Pain in the United States.
Schepman PB; Thakkar S; Robinson RL; Beck CG; Malhotra D; Emir B; Hansen RN
J Health Econ Outcomes Res; 2022; 9(1):58-67. PubMed ID: 35620454
[No Abstract] [Full Text] [Related]
34. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
35. Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia.
Zhao Y; Sun P; Bernauer M
J Pain Res; 2012; 5():443-51. PubMed ID: 23152695
[TBL] [Abstract][Full Text] [Related]
36. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
[TBL] [Abstract][Full Text] [Related]
37. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
[TBL] [Abstract][Full Text] [Related]
38. Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA.
Estes SJ; Soliman AM; Zivkovic M; Chopra D; Zhu X
Adv Ther; 2020 Jun; 37(6):2777-2791. PubMed ID: 32399813
[TBL] [Abstract][Full Text] [Related]
39. Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study.
DerSarkissian M; Gu YM; Duh MS; Benson J; Huang SP; Averell C; Vu J; Wang MJ; Bell CF
ACR Open Rheumatol; 2023 Jun; 5(6):318-328. PubMed ID: 37226045
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
